Previous Close | 2.7000 |
Open | 2.7200 |
Bid | 0.0000 x 1300 |
Ask | 0.0000 x 800 |
Day's Range | 2.4800 - 2.7500 |
52 Week Range | 2.1000 - 18.1700 |
Volume | 157,451 |
Avg. Volume | 251,532 |
Market Cap | 78M |
Beta (5Y Monthly) | 1.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | 2016-01-12 |
1y Target Est | N/A |
Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will attend the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2019 in Boston and the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 in New York, NY.
If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a measure of share...
PolarityTE, Inc. (NASDAQ:PTE) shareholders should be happy to see the share price up 11% in the last week. But that...
PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
The big shareholder groups in PolarityTE, Inc. (NASDAQ:PTE) have power over the company. Institutions will often hold...
PolarityTE presented final results from a pilot study on the use of its SkinTE product for hard-to-treat diabetic foot ulcers, or DFUs, as a poster, which showed that 10 of the 11 patients evaluated in the study had healed DFUs within eight weeks of SkinTE application, with a mean time to heal of 29.7 days. SkinTE is an autologous, homologous human cellular and tissue-based product capable of regenerating full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. PolaityTE said the abstract will be published in the online supplement to the journal Diabetes later this year.
The 24th Electronic Entertainment Expo (E3) kicks off June 11 in Los Angeles, but the news is already flowing this weekend, with many gaming companies showcasing their biggest announcements and presentations. ...
The following companies can be considered "falling knives" because their share prices have declined more than 59% over the past 52 weeks through May 30. Wall Street is also optimistic about them as it issued recommendation ratings ranging from overweight to buy with average target prices that produce at least 135% stock appreciation within 52 weeks. Warning! GuruFocus has detected 3 Warning Signs with PTE.
PolarityTE (PTE) needs investors to pay close attention to the stock based on moves in the options market lately.
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in PolarityTE, Inc. (NASDAQ:PTE), then you might want to consider its beta (a me...
Shares drop after the company announces that it is raising capital. Here are the must-know details for investors.
Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.
PolarityTE said the SEC subpoenaed it earlier this month for documents related to any promotion of the company or its securities, among other items.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examplesRead More...
Traders cheered after some positive regulatory news emerged.
Polarity (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured expert Kevin Matras highlights: Shenandoah Telecommunications, Honda Motor, PolarityTE, Ubiquiti Networks and Titan Machinery
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Attractive stocks have exceptional fundamentals. In the Read More...